Company / Shareholders' Equity
AYTU BIOPHARMA, INC Shareholders' Equity History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$19.0M
FY2025
5-year range
$19.0M / $137.6M
FY2021-FY2025
Trend
-31.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 4 consecutive years, from $138M in FY2021 to $19M in FY2025.
Based on SEC 10-K filings.
$19M in FY2025 with a 10-year CAGR of +2.0%.
Declined from $39M to $19M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -24.6%
- 5-Year CAGR
- -27.6%
- 10-Year CAGR
- +2.0%
Key checks
Key Insights
- AYTU BIOPHARMA, INC's shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -27.6%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 31.6% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.0M | -31.6% |
| FY2024 | $27.7M | -29.6% |
| FY2023 | $39.4M | -11.2% |
| FY2022 | $44.3M | -67.8% |
| FY2021 | $137.6M | +44.8% |
| FY2020 | $95.0M | +607.8% |
| FY2018 | $13.4M | +235.6% |
| FY2017 | $4.0M | -60.3% |
| FY2016 | $10.1M | -35.4% |
| FY2015 | $15.6M | +59.2% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026